News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Summit Therapeutics (SMMT) is currently assessed as 52% undervalued, with a fair value estimated at $28.36 against its closing price of $13.76. This valuation is largely based on ambitious assumptions regarding its ivonescimab program, which recently expanded with a new global Phase II/III bladder …
Sharemaestro market context Price below Trend Line 52 weeks -31.8% · Next-week setup negative 7.4%Summit Therapeutics has launched the HARMONi-GU1 trial, a global Phase II/III study evaluating ivonescimab in combination with an antibody-drug conjugate for bladder cancer. Ivonescimab is a bispecific antibody that blocks both PD-1 and VEGF pathways. This trial represents an expansion of Summit's HARMONi program, …
This article provides stock information for Sumitomo Mitsui Financial Group ADR (SMFG-N), including its current price, historical data, and related news. It details the company's profile as a financial holding company with various functions and subsidiaries. The page also lists market data, analyst ratings, …
Consumer Portfolio Services (CPSS) announced its Q2 2026 financial results, reporting a diluted EPS of $0.27, a 35% increase year-over-year, and net income of $6.2 million. The company's revenue climbed 10.6% to $121.4 million, with its total portfolio balance reaching $4.31 billion. Wall Street …
Summit Therapeutics (NASDAQ: SMMT) has initiated the global Phase II/III HARMONi-GU1 study for ivonescimab in urothelial carcinoma (bladder cancer). This randomized trial will evaluate ivonescimab plus enfortumab vedotin against pembrolizumab plus enfortumab vedotin as a first-line treatment for locally advanced or metastatic urothelial carcinoma, …
The article discusses the algorithmic entry frameworks for Summit State Bank (NASDAQ: SSBI), highlighting weak near and mid-term sentiment but a strong long-term outlook. It presents institutional trading strategies, including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis. The analysis …
This page provides comprehensive information on Consumer Portfolio Services, Inc. (CPSS), including its current stock price, financial metrics, and a history of news and press releases. The company specializes in automobile financing for consumers with less-than-perfect credit. Recent news highlights include strong Q2 2026 …
Summit Hotel Properties (INN) exceeded Wall Street expectations for its second-quarter earnings, reporting funds from operations (FFO) of $34.9 million, or 29 cents per share, surpassing the average analyst estimate of 28 cents per share. The real estate investment trust, specializing in higher-end hotels, …
UBS Group AG and its subsidiaries have disclosed an 8.08% beneficial ownership stake in Summit Hotel Properties, Inc., totaling 8,757,861 shares of common stock, through a Schedule 13G filing. The filing indicates shared voting power over 8,753,313 shares and shared dispositive power over all …
DBS maintained a Buy rating on Sumitomo Mitsui Financial Group (SMFNF) with a price target of Yen7,660.00. Analyst Lim Rui Wen, who covers the Financial sector, has an average return of 22.6% and an 81.58% success rate on recommended stocks. Despite a "Strong Buy" …
Legacy Ridge Capital Management sold its stake in Summit Midstream Corporation (SMC) in the first half of 2026, admitting it was a "massive investing mistake" dating back to 2017. Despite some improvements under CEO Heath Deneke, the firm felt a more aggressive strategy for …
HARMONi-GU1 Is First Global Registrational Clinical Trial of Ivonescimab in a Genitourinary (GU) Cancer, Adding to Global Phase III Ivonescimab Studies in NSCLC and CRC Clinical Trial Site Activations Globally Planned to Begin by Q4 2026 MIAMI, August 05, 2026--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: …
Sharemaestro market context Price below Trend Line 52 weeks -31.8% · Next-week setup negative 7.4%Edgestream Partners L.P. has acquired a new position in Reynolds Consumer Products Inc. (NASDAQ:REYN), purchasing 69,075 shares valued at approximately $1.463 million in the first quarter. This comes as several other hedge funds have also adjusted their holdings in REYN. Analysts have issued an …
Consumer Portfolio Services (CPSS) reported a strong Q2 2026, with net income rising 30% to $6.2 million and diluted EPS increasing 35% to $0.27. Revenues reached $121.4 million, and new contract purchases surged 75% to $757.7 million, driving a 10.6% revenue increase. The company …
Consumer Portfolio Services (CPSS) reported a significant increase in its second-quarter 2026 financial results, with net income rising 30% to $6.2 million and revenue increasing 10.6% to $121.4 million. The company also saw new contract purchases jump by 75% to $757.7 million. Insider trading …
Consumer Portfolio Services (CPSS) announced robust second-quarter 2026 results, with net income rising 30% to $6.2 million and diluted EPS increasing 35% to $0.27. Revenues climbed 10.6% to $121.4 million, driven by a 75% surge in new contract purchases, totaling $757.7 million. The company's …
Search by ticker symbol or company name and select a result to open its chart.